GARY ROTSTEIN – Pittsburgh Post-Gazette,
November 26, 2012

It has been a frustrating year — a depressing decade, in fact — for people hoping for breakthroughs in Alzheimer’s research and treatment. — Two pharmaceutical giants invested hundreds of millions of dollars in an intravenous drug treatment known as Bapineuzumab, which was supposed to reverse the symptoms of Alzheimer’s by erasing amyloid plaque that clogs the brain as one possible telltale sign of the disease.

Pfizer and Johnson & Johnson announced in August that they were discontinuing work on the drug as a failure, after study participants got their hopes up that they were assisting in an overdue advance in battling a global increase in dementia.

Pittsburgh Post-Gazette, November 26, 2012,